Top Stories
FDA Priority Review Puts Merck Belzutifan-Keytruda Combo on Fast Track for ccRCC Approval
According to OncLive, the FDA has granted priority review to Mercks supplemental new drug application seeking approval of belzutifan plus pembrolizumab for treatment of advanced clear cell renal cell carcinoma. The combination targets both HIF-2alpha and PD-1 pathways simultaneously, representing a novel dual mechanism approach in first-line RCC. Merck filed the sNDA based on Phase 3 LITESPARK-005 trial data demonstrating superior progression-free survival versus pembrolizumab alone. The priority review designation sets a six-month review timeline, positioning potential approval for mid-2026. If approved, Merck adds a differentiated first-line RCC option to its Keytruda franchise, extending the blockbuster into HIF-pathway biology. Exelixis and Eisai face increased competition in the crowded first-line RCC market where cabozantinib-nivolumab and lenvatinib-pembrolizumab combinations currently compete. The FDA action date will determine whether belzutifan becomes the first approved HIF-2alpha inhibitor in combination therapy. BioPharma Dive notes this represents Mercks fifth Keytruda combination under regulatory review across solid tumors.
Kyowa Kirin Abandons Rocatinlimab After Kaposi Sarcoma Cases Derail OX40 Program
BioPharma Dive reported that Kyowa Kirin has discontinued development of rocatinlimab, its OX40 monoclonal antibody for atopic dermatitis, following identification of Kaposi sarcoma cases in clinical trials. The company conducted a comprehensive safety review after multiple patients developed the rare vascular tumor, leading to immediate termination of all rocatinlimab studies. Rocatinlimab had been positioned as a potential best-in-class OX40 inhibitor with differentiated efficacy data in moderate-to-severe atopic dermatitis. According to BioPharma Dive, the Kaposi sarcoma link suggests deeper safety concerns with OX40 pathway modulation that may impact the entire drug class. Kyowa Kirin loses its lead dermatology asset and faces write-downs on clinical investment exceeding 300 million dollars. The discontinuation raises questions about whether other OX40-targeted programs from Sanofi and Amgen will face similar regulatory scrutiny. Endpoints News notes this marks the third high-profile immunology asset failure in 2026 after safety signals derailed competitive programs. The broader OX40 class faces increased regulatory skepticism, potentially delaying approvals across all indications.
ASCO GU 2026 Prostate Data Show Hypofractionated Radiation Gains Traction in Post-Surgical Setting
CancerNetwork reported key prostate cancer abstracts from ASCO GU 2026 demonstrating that hypofractionated radiation therapy delivers non-inferior outcomes versus conventional fractionation schedules in post-prostatectomy patients. The NRG Oncology trial NCT03274687 enrolled 1,180 stage I-II prostate adenocarcinoma patients randomized to hypofractionated versus standard radiation, with primary endpoint data showing equivalent biochemical recurrence-free survival at five years. According to CancerNetwork, the shorter treatment course reduces patient burden from 35 daily fractions to 20 fractions over four weeks while maintaining efficacy. ClinicalTrials.gov lists the trial status as active not recruiting, indicating final survival data collection is ongoing. Radiation oncology practices can adopt hypofractionated protocols as standard of care, improving throughput and patient convenience without compromising outcomes. The data support broader adoption of moderately hypofractionated regimens across intermediate-risk prostate cancer populations. Per CancerNetwork, additional abstracts at ASCO GU 2026 examined hormonal therapy intensification strategies, though results were mixed across different risk stratifications. Pharmaceutical companies developing long-acting hormonal agents face reduced differentiation if radiation schedule compression becomes standard practice.
Pipeline Watch
Suzhou Suncadia Biopharmaceuticals has opened enrollment in NCT07393542, evaluating novel agent SHR-A2102 combined with PD-L1 inhibitor adebrelimab in locally advanced or metastatic urothelial carcinoma, per ClinicalTrials.gov. The Phase 2/3 trial targets patients who progressed on or after platinum-based chemotherapy, a setting where immune checkpoint inhibitors show variable response rates. SHR-A2102 mechanism of action has not been publicly disclosed, positioning this as a potential first-in-class combination if trial data demonstrate synergistic activity. Enrollment is ongoing across sites in China.
The National Cancer Institute continues long-term follow-up in NCT00217737, a trial comparing FOLFOX chemotherapy with or without bevacizumab in stage IIA colon adenocarcinoma patients following surgical resection, according to ClinicalTrials.gov. The study has completed enrollment with active not recruiting status, suggesting investigators are collecting survival endpoint data. Stage II colon cancer represents a controversial adjuvant treatment setting where chemotherapy benefit remains marginal and biomarker selection is critical. Final results will inform whether adding bevacizumab to oxaliplatin-based regimens improves disease-free survival in this moderate-risk population.
NRG Oncology has completed patient accrual in NCT03274687, the definitive trial comparing hypofractionated versus conventional radiation therapy schedules in post-prostatectomy prostate adenocarcinoma, per ClinicalTrials.gov. The study enrolled patients with stage I disease following radical prostatectomy, randomizing them to shortened radiation courses versus standard 35-fraction protocols. Trial status shows active not recruiting, indicating the final survival and toxicity data collection phase is underway. Results will determine whether hypofractionated regimens become standard practice for adjuvant or salvage radiation in prostate cancer.
The American Society of Clinical Oncology announced its 2026 Science and Education Program digital cover art competition, inviting submissions from oncology trainees and early-career professionals, according to OncoDaily. Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, promoted the competition highlighting opportunities for emerging voices in oncology to showcase visual representations of cancer research themes. The initiative aims to engage younger oncology professionals in creative science communication ahead of the June 2026 annual meeting. Winning submissions will be featured across ASCO digital platforms.
The six-month priority review clock for belzutifan plus pembrolizumab in clear cell renal cell carcinoma positions a potential FDA decision for August or September 2026, per OncLive. Merck filed the supplemental new drug application based on Phase 3 LITESPARK-005 data showing progression-free survival benefit over pembrolizumab monotherapy in treatment-naive advanced RCC patients. Approval would make belzutifan the first HIF-2alpha inhibitor approved in combination with immunotherapy, opening a new mechanistic class in first-line kidney cancer. The priority review designation reflects FDA assessment of significant improvement over existing therapies.
Kyowa Kirins decision to discontinue rocatinlimab development extends beyond atopic dermatitis to all indications under investigation, BioPharma Dive reported. The OX40 monoclonal antibody was being evaluated in multiple inflammatory conditions including asthma and alopecia areata, all of which have been terminated following Kaposi sarcoma cases identified during safety monitoring. The breadth of program discontinuation suggests the safety signal is mechanism-based rather than indication-specific, raising fundamental questions about OX40 pathway modulation. Kyowa Kirin has not disclosed the total number of Kaposi sarcoma cases observed or their clinical characteristics.
Competitive Landscape
According to OncLive, FDA priority review of belzutifan-pembrolizumab positions Merck to enter the crowded first-line clear cell RCC market currently dominated by three combination regimens. Merck gains differentiation through HIF-2alpha pathway targeting, offering nephrologists a mechanistically distinct option versus dual checkpoint or TKI-IO combinations. Exelixis cabozantinib-nivolumab, Eisai lenvatinib-pembrolizumab, and Bristol Myers Squibb nivolumab-ipilimumab currently split first-line market share. The addition of a fourth approved combination will intensify prescriber choice complexity and likely compress pricing across the category.
| Company | Combination | Mechanism | Status |
|---|---|---|---|
| Merck | Belzutifan-Pembro | HIF-2a + PD-1 | Priority Review |
| BMS | Nivo-Ipi | PD-1 + CTLA-4 | Approved |
| Exelixis | Cabo-Nivo | TKI + PD-1 | Approved |
| Eisai | Lenva-Pembro | TKI + PD-1 | Approved |
BioPharma Dive reported that rocatinlimab discontinuation raises regulatory hurdles for competing OX40 programs from Sanofi and Amgen, both of which are evaluating OX40 antagonists in earlier-stage dermatology trials. The entire OX40 class faces increased FDA safety monitoring requirements and potential clinical hold risk if additional Kaposi sarcoma cases emerge across programs. Investigators will scrutinize whether the safety signal is antibody-specific or represents an on-target class effect from OX40 pathway inhibition. No other OX40 programs have reported similar adverse events to date.
CancerNetwork reported that hypofractionated radiation non-inferiority data from NRG Oncology trial NCT03274687 will accelerate practice pattern changes across community and academic radiation centers. Radiation oncology departments can increase patient throughput by 40 percent while maintaining outcomes, improving operational efficiency and patient satisfaction. The shift away from 35-fraction standard protocols to 20-fraction regimens reduces radiation therapy costs and improves resource utilization. Radiation equipment manufacturers may see increased demand as centers optimize capacity.
Forward Looking
- Watch for FDA action date announcement on belzutifan-pembrolizumab sNDA in coming weeks, which will set firm approval timeline and trigger RCC market positioning by Merck commercial team ahead of mid-2026 launch.
- Monitor whether competing OX40 programs from Sanofi and Amgen implement protocol amendments or enhanced Kaposi sarcoma screening following Kyowa Kirin rocatinlimab discontinuation, signaling class-wide regulatory caution.
- Track radiation oncology society guideline updates incorporating ASCO GU 2026 hypofractionation data, which will determine speed of practice pattern adoption across post-prostatectomy treatment protocols.
- Anticipate Suzhou Suncadia disclosure of SHR-A2102 mechanism of action as NCT07393542 urothelial carcinoma trial progresses, revealing whether the agent represents novel target biology versus biosimilar strategy in bladder cancer.